{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:34:53Z","timestamp":1791484493121,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41591-024-03280-4","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T10:02:32Z","timestamp":1728036152000},"page":"3555-3567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Noninvasive, microbiome-based diagnosis of inflammatory bowel disease"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4248-4395","authenticated-orcid":false,"given":"Jiaying","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianru","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1634-3780","authenticated-orcid":false,"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-4933","authenticated-orcid":false,"given":"Whitney","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Pan","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Wilson O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Chen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8041-3574","authenticated-orcid":false,"given":"Charles N.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene B.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9257-9133","authenticated-orcid":false,"given":"Mark","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Kamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K. L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-3398","authenticated-orcid":false,"given":"Jingwan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-4454","authenticated-orcid":false,"given":"Siew C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"3280_CR1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"GBD 2017 Inflammatory Bowel Disease Collaborators.","year":"2020","unstructured":"GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 17\u201330 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"3280_CR2","first-page":"193","volume":"12","author":"SC Ng","year":"2016","unstructured":"Ng, S. C. Emerging trends of inflammatory bowel disease in Asia. Gastroenterol. Hepatol. (N. Y.) 12, 193\u2013196 (2016).","journal-title":"Gastroenterol. Hepatol. (N. Y.)"},{"key":"3280_CR3","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769\u20132778 (2017).","journal-title":"Lancet"},{"key":"3280_CR4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2023.03.238","volume":"165","author":"AJ Noble","year":"2023","unstructured":"Noble, A. J., Nowak, J. K., Adams, A. T., Uhlig, H. H. & Satsangi, J. Defining interactions between the genome, epigenome, and the environment in inflammatory bowel disease: progress and prospects. Gastroenterology 165, 44\u201360 (2023).","journal-title":"Gastroenterology"},{"key":"3280_CR5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrgastro.2017.136","volume":"15","author":"AN Ananthakrishnan","year":"2018","unstructured":"Ananthakrishnan, A. N. et al. Environmental triggers in IBD: a review of progress and evidence. Nat. Rev. Gastroenterol. Hepatol. 15, 39\u201349 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"3280_CR6","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1136\/gutjnl-2017-314519","volume":"66","author":"S Danese","year":"2017","unstructured":"Danese, S., Fiorino, G. & Peyrin-Biroulet, L. Early intervention in Crohn\u2019s disease: towards disease modification trials. Gut 66, 2179\u20132187 (2017).","journal-title":"Gut"},{"key":"3280_CR7","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D\u2019Haens","year":"2008","unstructured":"D\u2019Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial. Lancet 371, 660\u2013667 (2008).","journal-title":"Lancet"},{"key":"3280_CR8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/apt.17370","volume":"57","author":"N Jayasooriya","year":"2023","unstructured":"Jayasooriya, N. et al. Systematic review with meta-analysis: time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. Aliment. Pharm. Ther. 57, 635\u2013652 (2023).","journal-title":"Aliment. Pharm. Ther."},{"key":"3280_CR9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ueg2.12338","volume":"10","author":"J Zheng","year":"2022","unstructured":"Zheng, J., Sun, Q., Zhang, J. & Ng, S. C. The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis. United European Gastroenterol. J. 10, 1091\u20131102 (2022).","journal-title":"United European Gastroenterol. J."},{"key":"3280_CR10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.chom.2014.02.005","volume":"15","author":"D Gevers","year":"2014","unstructured":"Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn\u2019s disease. Cell Host Microbe 15, 382\u2013392 (2014).","journal-title":"Cell Host Microbe"},{"key":"3280_CR11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","volume":"149","author":"P Moayyedi","year":"2015","unstructured":"Moayyedi, P. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102\u2013109 (2015).","journal-title":"Gastroenterology"},{"key":"3280_CR12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/gutjnl-2017-314903","volume":"67","author":"C Palmela","year":"2018","unstructured":"Palmela, C. et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut 67, 574\u2013587 (2018).","journal-title":"Gut"},{"key":"3280_CR13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1053\/j.gastro.2020.09.036","volume":"160","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Elucidation of Proteus mirabilis as a key bacterium in Crohn\u2019s disease inflammation. Gastroenterology 160, 317\u2013330 (2021).","journal-title":"Gastroenterology"},{"key":"3280_CR14","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.cell.2022.07.003","volume":"185","author":"S Federici","year":"2022","unstructured":"Federici, S. et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell 185, 2879\u20132898 (2022).","journal-title":"Cell"},{"key":"3280_CR15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jcmgh.2022.11.005","volume":"15","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. Klebsiella pneumoniae induces inflammatory bowel disease through Caspase-11-mediated IL18 in the gut epithelial cells. Cell. Mol. Gastroenterol. Hepatol. 15, 613\u2013632 (2023).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"3280_CR16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2020.05.048","volume":"182","author":"S Kitamoto","year":"2020","unstructured":"Kitamoto, S. et al. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis. Cell 182, 447\u2013462 (2020).","journal-title":"Cell"},{"key":"3280_CR17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/jgh.12073","volume":"28","author":"T Fujimoto","year":"2013","unstructured":"Fujimoto, T. et al. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn\u2019s disease. J. Gastroenterol. Hepatol. 28, 613\u2013619 (2013).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"3280_CR18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000441768","volume":"93","author":"K Takahashi","year":"2016","unstructured":"Takahashi, K. et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn\u2019s disease. Digestion 93, 59\u201365 (2016).","journal-title":"Digestion"},{"key":"3280_CR19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2019.11.003","volume":"145","author":"KL Glassner","year":"2020","unstructured":"Glassner, K. L., Abraham, B. P. & Quigley, E. M. M. The microbiome and inflammatory bowel disease. J. Allergy Clin. Immunol. 145, 16\u201327 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"3280_CR20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.22547","volume":"120","author":"C Veltkamp","year":"2001","unstructured":"Veltkamp, C. et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg\u03f526 mice. Gastroenterology 120, 900\u2013913 (2001).","journal-title":"Gastroenterology"},{"key":"3280_CR21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","volume":"4","author":"EA Franzosa","year":"2019","unstructured":"Franzosa, E. A. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat. Microbiol 4, 293\u2013305 (2019).","journal-title":"Nat. Microbiol"},{"key":"3280_CR22","volume":"14","author":"L Ning","year":"2023","unstructured":"Ning, L. et al. Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts. Nat. Commun. 14, 7135 (2023).","journal-title":"Nat. Commun."},{"key":"3280_CR23","doi-asserted-by":"crossref","first-page":"716604","DOI":"10.3389\/fcell.2021.716604","volume":"9","author":"M Pratt","year":"2021","unstructured":"Pratt, M., Forbes, J. D., Knox, N. C., Bernstein, C. N. & Van Domselaar, G. Microbiome-mediated immune signaling in inflammatory bowel disease and colorectal cancer: support from meta-omics data. Front. Cell Dev. Biol. 9, 716604 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"3280_CR24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01973-8","volume":"8","author":"C Duvallet","year":"2017","unstructured":"Duvallet, C., Gibbons, S. M., Gurry, T., Irizarry, R. A. & Alm, E. J. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat. Commun. 8, 1784 (2017).","journal-title":"Nat. Commun."},{"key":"3280_CR25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/tjem.tjem_182_23","volume":"23","author":"K \u00c7orbac\u0131o\u011flu \u015e","year":"2023","unstructured":"\u00c7orbac\u0131o\u011flu \u015e, K. & Aksel, G. Receiver operating characteristic curve analysis in diagnostic accuracy studies: a guide to interpreting the area under the curve value. Turk. J. Emerg. Med. 23, 195\u2013198 (2023).","journal-title":"Turk. J. Emerg. Med."},{"key":"3280_CR26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrmicro2243","volume":"8","author":"S Sauer","year":"2010","unstructured":"Sauer, S. & Kliem, M. Mass spectrometry tools for the classification and identification of bacteria. Nat. Rev. Microbiol. 8, 74\u201382 (2010).","journal-title":"Nat. Rev. Microbiol."},{"key":"3280_CR27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1373\/clinchem.2014.221770","volume":"61","author":"R Patel","year":"2015","unstructured":"Patel, R. MALDI-TOF MS for the diagnosis of infectious diseases. Clin. Chem. 61, 100\u2013111 (2015).","journal-title":"Clin. Chem."},{"key":"3280_CR28","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature07540","volume":"457","author":"PJ Turnbaugh","year":"2009","unstructured":"Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480\u2013484 (2009).","journal-title":"Nature"},{"key":"3280_CR29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature11711","volume":"493","author":"S Schloissnig","year":"2013","unstructured":"Schloissnig, S. et al. Genomic variation landscape of the human gut microbiome. Nature 493, 45\u201350 (2013).","journal-title":"Nature"},{"key":"3280_CR30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bios.2018.07.041","volume":"118","author":"J Zhang","year":"2018","unstructured":"Zhang, J., Wang, J., Zhang, X. & He, F. Rapid detection of Escherichia coli based on 16S rDNA nanogap network electrochemical biosensor. Biosens. Bioelectron. 118, 9\u201315 (2018).","journal-title":"Biosens. Bioelectron."},{"key":"3280_CR31","doi-asserted-by":"crossref","first-page":"13734","DOI":"10.1002\/anie.201407606","volume":"53","author":"W Chen","year":"2014","unstructured":"Chen, W. et al. Identification of bacteria in water by a fluorescent array. Angew. Chem. Int. Ed. Engl. 53, 13734\u201313739 (2014).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"3280_CR32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1373\/clinchem.2019.302315","volume":"65","author":"W Chen","year":"2019","unstructured":"Chen, W. et al. Breast cancer subtype classification using 4-plex droplet digital PCR. Clin. Chem. 65, 1051\u20131059 (2019).","journal-title":"Clin. Chem."},{"key":"3280_CR33","doi-asserted-by":"crossref","DOI":"10.1016\/j.mimet.2020.106044","volume":"177","author":"AS Lewin","year":"2020","unstructured":"Lewin, A. S. et al. Multiplex droplet digital PCR assay for detection of Flavobacterium psychrophilum and Yersinia ruckeri in Norwegian aquaculture. J. Microbiol. Methods 177, 106044 (2020).","journal-title":"J. Microbiol. Methods"},{"key":"3280_CR34","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1373\/clinchem.2013.206359","volume":"59","author":"V Taly","year":"2013","unstructured":"Taly, V. et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin. Chem. 59, 1722\u20131731 (2013).","journal-title":"Clin. Chem."},{"key":"3280_CR35","unstructured":"Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests - Guidance for Industry and FDA Staff (Center for Devices and Radiological Health, 2007); https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/statistical-guidance-reporting-results-studies-evaluating-diagnostic-tests-guidance-industry-and-fda"},{"key":"3280_CR36","volume":"11","author":"Y Ma","year":"2021","unstructured":"Ma, Y. et al. Metagenome analysis of intestinal bacteria in healthy people, patients with inflammatory bowel disease and colorectal cancer. Front. Cell Infect. Microbiol 11, 599734 (2021).","journal-title":"Front. Cell Infect. Microbiol"},{"key":"3280_CR37","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655\u2013662 (2019).","journal-title":"Nature"},{"key":"3280_CR38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2004.04.061","volume":"127","author":"A Darfeuille-Michaud","year":"2004","unstructured":"Darfeuille-Michaud, A. et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn\u2019s disease. Gastroenterology 127, 412\u2013421 (2004).","journal-title":"Gastroenterology"},{"key":"3280_CR39","doi-asserted-by":"crossref","first-page":"eaap8914","DOI":"10.1126\/scitranslmed.aap8914","volume":"10","author":"A Vich Vila","year":"2018","unstructured":"Vich Vila, A. et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci. Transl. Med. 10, eaap8914 (2018).","journal-title":"Sci. Transl. Med."},{"key":"3280_CR40","doi-asserted-by":"crossref","first-page":"203\u2013214","DOI":"10.1016\/j.chom.2018.02.004","volume":"23","author":"L Chung","year":"2018","unstructured":"Chung, L. et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe 23, 203\u2013214 (2018).","journal-title":"Cell Host Microbe"},{"key":"3280_CR41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3201\/eid0602.000210","volume":"6","author":"TP Prindiville","year":"2000","unstructured":"Prindiville, T. P. et al. Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg. Infect. Dis. 6, 171\u2013174 (2000).","journal-title":"Emerg. Infect. Dis."},{"key":"3280_CR42","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1469-0691.2006.01494.x","volume":"12","author":"NU Toprak","year":"2006","unstructured":"Toprak, N. U. et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin. Microbiol Infect. 12, 782\u2013786 (2006).","journal-title":"Clin. Microbiol Infect."},{"key":"3280_CR43","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00616-22","volume":"10","author":"A Pisani","year":"2022","unstructured":"Pisani, A. et al. Dysbiosis in the gut microbiota in patients with inflammatory bowel disease during remission. Microbiol. Spectr. 10, e0061622 (2022).","journal-title":"Microbiol. Spectr."},{"key":"3280_CR44","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature11552","volume":"489","author":"V Tremaroli","year":"2012","unstructured":"Tremaroli, V. & B\u00e4ckhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 489, 242\u2013249 (2012).","journal-title":"Nature"},{"key":"3280_CR45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.chom.2023.01.009","volume":"31","author":"EM Brown","year":"2023","unstructured":"Brown, E. M., Clardy, J. & Xavier, R. J. Gut microbiome lipid metabolism and its impact on host physiology. Cell Host Microbe 31, 173\u2013186 (2023).","journal-title":"Cell Host Microbe"},{"key":"3280_CR46","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.575455","volume":"11","author":"K Hiippala","year":"2020","unstructured":"Hiippala, K. et al. Novel Odoribacter splanchnicus strain and its outer membrane vesicles exert immunoregulatory effects in vitro. Front. Microbiol. 11, 575455 (2020).","journal-title":"Front. Microbiol."},{"key":"3280_CR47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41579-019-0213-6","volume":"17","author":"M Schirmer","year":"2019","unstructured":"Schirmer, M., Garner, A., Vlamakis, H. & Xavier, R. J. Microbial genes and pathways in inflammatory bowel disease. Nat. Rev. Microbiol. 17, 497\u2013511 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"3280_CR48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","volume":"7","author":"DJ Morrison","year":"2016","unstructured":"Morrison, D. J. & Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7, 189\u2013200 (2016).","journal-title":"Gut Microbes"},{"key":"3280_CR49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/nutrit\/nuac039","volume":"81","author":"Y Ji","year":"2022","unstructured":"Ji, Y. et al. Insights into diet-associated oxidative pathomechanisms in inflammatory bowel disease and protective effects of functional amino acids. Nutr. Rev. 81, 95\u2013113 (2022).","journal-title":"Nutr. Rev."},{"key":"3280_CR50","volume":"13","author":"Q Su","year":"2022","unstructured":"Su, Q. et al. Faecal microbiome-based machine learning for multi-class disease diagnosis. Nat. Commun. 13, 6818 (2022).","journal-title":"Nat. Commun."},{"key":"3280_CR51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/1751-2980.12795","volume":"20","author":"YJ Weng","year":"2019","unstructured":"Weng, Y. J. et al. Correlation of diet, microbiota and metabolite networks in inflammatory bowel disease. J. Dig. Dis. 20, 447\u2013459 (2019).","journal-title":"J. Dig. Dis."},{"key":"3280_CR52","doi-asserted-by":"crossref","first-page":"gix050","DOI":"10.1093\/gigascience\/gix050","volume":"6","author":"Q He","year":"2017","unstructured":"He, Q. et al. Two distinct metacommunities characterize the gut microbiota in Crohn\u2019s disease patients. Gigascience 6, gix050 (2017).","journal-title":"Gigascience"},{"key":"3280_CR53","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.cell.2020.08.007","volume":"182","author":"RAT Mars","year":"2020","unstructured":"Mars, R. A. T. et al. Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome. Cell 182, 1460\u20131473 (2020).","journal-title":"Cell"},{"key":"3280_CR54","volume":"9","author":"AB Hall","year":"2017","unstructured":"Hall, A. B. et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med. 9, 103 (2017).","journal-title":"Genome Med."},{"key":"3280_CR55","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2939","volume":"32","author":"HB Nielsen","year":"2014","unstructured":"Nielsen, H. B. et al. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes. Nat. Biotechnol. 32, 822\u2013828 (2014).","journal-title":"Nat. Biotechnol."},{"key":"3280_CR56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41564-017-0089-z","volume":"3","author":"M Schirmer","year":"2018","unstructured":"Schirmer, M. et al. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nat. Microbiol 3, 337\u2013346 (2018).","journal-title":"Nat. Microbiol"},{"key":"3280_CR57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1126\/science.aad3369","volume":"352","author":"A Zhernakova","year":"2016","unstructured":"Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565\u2013569 (2016).","journal-title":"Science"},{"key":"3280_CR58","doi-asserted-by":"crossref","first-page":"e0172605","DOI":"10.1371\/journal.pone.0172605","volume":"12","author":"UZ Ijaz","year":"2017","unstructured":"Ijaz, U. Z. et al. The distinct features of microbial \u2018dysbiosis\u2019 of Crohn\u2019s disease do not occur to the same extent in their unaffected, genetically-linked kindred. PLoS ONE 12, e0172605 (2017).","journal-title":"PLoS ONE"},{"key":"3280_CR59","volume":"6","author":"Q Feng","year":"2015","unstructured":"Feng, Q. et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat. Commun. 6, 6528 (2015).","journal-title":"Nat. Commun."},{"key":"3280_CR60","doi-asserted-by":"crossref","first-page":"766","DOI":"10.15252\/msb.20145645","volume":"10","author":"G Zeller","year":"2014","unstructured":"Zeller, G. et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol. Syst. Biol. 10, 766 (2014).","journal-title":"Mol. Syst. Biol."},{"key":"3280_CR61","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-019-0406-6","volume":"25","author":"J Wirbel","year":"2019","unstructured":"Wirbel, J. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 25, 679\u2013689 (2019).","journal-title":"Nat. Med."},{"key":"3280_CR62","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41591-019-0458-7","volume":"25","author":"S Yachida","year":"2019","unstructured":"Yachida, S. et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat. Med. 25, 968\u2013976 (2019).","journal-title":"Nat. Med."},{"key":"3280_CR63","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature12506","volume":"500","author":"E Le Chatelier","year":"2013","unstructured":"Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541\u2013546 (2013).","journal-title":"Nature"},{"key":"3280_CR64","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nmeth.4468","volume":"14","author":"E Pasolli","year":"2017","unstructured":"Pasolli, E. et al. Accessible, curated metagenomic data through ExperimentHub. Nat. Methods 14, 1023\u20131024 (2017).","journal-title":"Nat. Methods"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03280-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T14:35:35Z","timestamp":1738679735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03280-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3280"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03280-4","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"17 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C.N. has served as an advisory board member for Pfizer, Ferring, Janssen and Abbvie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie and Takeda; has received research grants through her affiliated institutions from Olympus, Ferring and Abbvie; is a founder member, nonexecutive director, nonexecutive scientific advisor and shareholder of GenieBiome Ltd; and receives patent royalties through her affiliated institutions. F.K.L.C. is a Board Member of CUHK Medical Centre; is a cofounder, nonexecutive Board Chairman, nonexecutive scientific advisor, Honorary Chief Medical Officer and shareholder of GenieBiome Ltd; receives patent royalties through his affiliated institutions; and has received fees as an advisor and honoraria as a speaker for Eisai Co. Ltd, AstraZeneca, Pfizer Inc., Takeda Pharmaceutical Co. and Takeda (China) Holdings Co. Ltd. Q. Su and Z.X. are Scientists (Diagnostics) of GenieBiome Ltd. W.T. is Consultant (Regulatory Affairs) of GenieBiome Ltd. J. Zhang is Chief Scientist (Diagnostics) of GenieBiome Ltd. J. Zheng, W.T., J. Zhang, F.K.L.C. and S.C.N. are named inventors of patent applications held by MagIC that cover the therapeutic and diagnostic use of microbiome related to IBD (nos. 63\/562,232; 63\/675,266; 63\/689,864 USA, 2024). C.N.B. is supported by the Bingham Chair in Gastroenterology; has served on advisory Boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, Ferring Canada, JAMP Pharmaceuticals, Lilly Canada, Janssen Canada, Pendopharm Canada, Sandoz Canada, Takeda Canada and Pfizer Canada; has received educational grants from Abbvie Canada, Bristol Myers Squibb Canada, Ferring Canada, organon Canada, Pfizer Canada, Takeda Canada, Boston Scientific and Janssen Canada; has served on a Speaker\u2019s panel for Abbvie Canada, Janssen Canada, Pfizer Canada and Takeda Canada; and has received research funding from Abbvie Canada, Amgen Canada, Sandoz Canada, Takeda Canada and Pfizer Canada. D.T.R. has received grant support from Takeda and has served as a consultant for Abbvie, Altrubio, Amgen, Bausch Health, Bristol Myers Squibb, Connect BioPharma, Ferring Pharma, Image Analysis Group, Iterative Health, Janssen Pharmaceuticals, Lilly, Merck, Pfizer, Prometheus Biosciences (now Merck), Reistone Biopharma, USA, Takeda and Trellus Health. E.B.C. is Founder and Chief Scientific Officer of Gateway Biome, Inc. M.M. has received research grants from Soho Flordis International Australia Research, Bayer Steigerwald Arzneimittelwerk (Bayer Consumer Health) and Yakult-Nature Global Grant for Gut Health; Speaker\u2019s honoraria and travel sponsorship from Janssen Australia; consultancy fees from Bayer Steigerwald Arzneimittelwerk (Bayer Consumer Health), Sanofi Australia and Danone-Nutricia Australia; Speaker honoraria and travel sponsorship from Perfect Company (China); and travel sponsorship from Yakult Inc. (Japan); is coinventor of PCT\/AU2022\/050556 \u2018Diagnostic marker for functional gastrointestinal disorders\u2019 from the University of Newcastle and UniQuest (University of Queensland), and US20110076356 A1 \u2018Novel Fibro-biotic bacterium isolate\u2019 via the US Department of Agriculture; acknowledges funding from NHMRC Australia, Australian Research Council, Princess Alexandra Hospital Research Foundation, Medical Research Futures Fund of Australia, Helmsley Charitable Trust via the Australasian Gastrointestinal Research Foundation and the United States Department of Defense; and serves on the science advisory board (nonremunerated) for GenieBiome, Hong Kong. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}